High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2897-2903

  Fizazi, Karim ^a   Sikes, Charles R ^b   Kim, Jeri ^b   Yang, Jun ^b   Martinez, Luis A ^b   Olive, Matilde C ^b   Logothetis, Christopher J ^b   Navone, Nora M ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Docetaxel; Estramustine; Hormone; Metastases; Prostate cancer

Indexed keywords

ANDROGEN; DOCETAXEL; ESTRAMUSTINE;

ADOLESCENT; ADVANCED CANCER; ANDROGEN DEPRIVATION; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE LESION; BONE METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CASTRATION; CELL STRAIN MDA PCA 2B; CELL STRAIN PC3; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ESTRAMUSTINE; HUMANS; MALE; MICE; MICE, SCID; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 6444240067     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al: Chemotherapy with mitoxantrone plus prednisone in men with hormone-refractory prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14: 1756-1764, 1996.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506-2513, 1999.
3. Petrylak DP, McArthur RB, O'Connor J, Shelton G, Judge T, Balog J et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17: 958-967, 1999.
4. Oudard S, Beuzeboc P, Dourthe LM, Voog E, Hardy-Bessard AC et al: Preliminary results of a phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P) -two schedules- versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 21: 177a, 2002.
5. Navone NM, Logothetis CJ, von Eschenbach AC and Troncoso P: Model systems of prostate cancer: uses and limitations. Cancer Met Rev 17: 361-371, 1999.
6. Williams FF, Muenchen HJ, Kamradt JM, Korenchuk S and Pienta KJ: Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate 44: 275-278, 2000.
7. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM et al: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3: 2493-2500, 1997.
8. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH et al: TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6: 1190-1197, 2000.
9. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N et al: Prostate cancer cells induce osteoblast differentiation through a Cbfal-dependent pathway. Cancer Res 61: 5652-5659, 2001.
10. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ et al: The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 8: 775-781, 2002.
11. Bissery MC, Vrignaud P and Lavelle F: Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 22: 3-16, 1995.
12. Riou JF, Naudin A and Lavelle F: Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res 187: 164-170, 1992.
13. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al: Eligibility and response guideline for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467, 1999.
14. Stein CA: Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26: 3-7, 1999.
15. Haldar S, Basu A and Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
16. Muenchen HJ, Poncza PJ and Pienta KJ: Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC3. Urology 57: 366-370, 2001.
17. Wang LG, Liu XM, Kreis W and Budman DR: Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol 55: 1427-1433, 1998.
18. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H et al: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17: 3160-3166, 1999.
19. Berry W, Gregurich M, Dakhil S, Hathorn J and Asmar L: Phase II randomized trial of weekly paclitaxel (Taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP) (abstract). Proc Am Soc Clin Oncol 20: 175, 2001.